Drug Profile
CRL 8131
Alternative Names: Poloxamer 331; ProtoxLatest Information Update: 29 Sep 2022
Price :
$50
*
At a glance
- Originator CytRx Corporation
- Developer LadRx Corporation
- Class Antibacterials; Antiprotozoals; Antituberculars; Surfactants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Protozoan infections; Tuberculosis; Viral infections
Most Recent Events
- 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
- 28 Dec 2000 Discontinued-Preclinical for Protozoal infections in USA (Unknown route)
- 28 Dec 2000 Discontinued-Preclinical for Tuberculosis in USA (Unknown route)